Quinolone-containing liposome composition

Abstract

A liposome composition for treating a bacterial infection is described. The composition includes liposomes having a surface coating of hydrophilic polymer chains and an entrapped drug-conjugate composed of a quinolone compound conjugated to an amino acid.

Description

field of invention [0001] The present invention relates to compositions for the administration of quinolones for the treatment of bacterial infections, and more particularly to liposomal compositions for the administration of drug-conjugates of quinolones covalently linked to amino acids. [0002] references [0003] Chakrabarti, A. et al., US Patent 5,380,532, issued 1995, 1,10. [0004] Cramer, J. et al., Biochemical and Biophysical Research Communications 75(2):295-301 (1977). [0005] Culbertson, T.P. et al., J. Med. Chem. 33: 2270-2275 (1990). [0006] Deamer, D.W. et al., Biochim. et Biophys Acta 274:323 (1972). [0007] Domagala, J.M. et al., J. Medicinal Chemistry 29: 448-453 (1986). [0008] Greene, T.W. et al., Protecting Groups in Organic Synthesis, 2nd ed., John Wiley & Sons, New York, USA (1991). [0009] Hagen, S.E., et al., J. Medicinal Chemistry 33: 849-845 (1990). [0010] Hagen, S.E., et al., J. Medicinal Chemistry 34: 1155-1161 (1991). [0011] Hope, ...

AI Technical Summary

Problems solved by technology

[0030] However, a noteworthy issue with remote loading is that not all ionized drugs are aggregated on liposomes in response to ion gradients (Chakrabarti et al., 1995; Madden et al., 1990)

Another problem is that some reagents aggregated in liposomes are released immediately after aggregation

A further problem is that some agents that are successfully loaded and retained in liposomes in vitro have a high leakage rate from liposomes in vivo, which negates the advantages of liposomal agent delivery in an encapsulated form

Images